InstalabLoading...
InstalabLoading...
Your pancreas does not release insulin in its finished form. It first builds a larger molecule called proinsulin, then trims it into two pieces: mature insulin and a fragment called C-peptide. When the insulin-producing cells (called beta cells) are healthy and keeping up with demand, almost all of the proinsulin gets converted before it leaves the cell. But when those cells are overworked, stressed, or beginning to fail, they start releasing unconverted proinsulin into the bloodstream. That spillover is what this test catches.
What makes proinsulin uniquely valuable is timing. Standard blood sugar markers like glucose and HbA1c only budge once your body has lost a significant amount of its ability to regulate blood sugar. Proinsulin can rise years, even decades, before glucose does. In one study following men for 27 years, elevated proinsulin independently predicted who would develop type 2 diabetes, even after accounting for body weight and fasting glucose. That kind of early warning is hard to get from a routine lab panel.
Proinsulin (the full name for this precursor) is a single chain of about 86 amino acids that contains the blueprint for insulin within it. Inside each beta cell, proinsulin folds into its three-dimensional shape in a compartment called the endoplasmic reticulum (essentially the cell's protein-folding workshop). It then moves through an internal shipping system to storage compartments called secretory granules, where specialized cutting enzymes snip it into mature insulin and C-peptide.
In a healthy beta cell, over 99% of proinsulin gets fully converted before it is released. When the process works well, only a tiny amount of intact proinsulin leaks into the blood. When the process breaks down, whether from chronic overwork, metabolic stress, or intrinsic beta cell damage, that percentage climbs. The ratio of proinsulin to insulin in your blood is essentially a report card on how well your beta cells are handling their workload.
Proinsulin's ability to predict type 2 diabetes has been tested in several large, long-running studies. In the Uppsala Longitudinal Study, 874 men were followed from age 50 for 27 years. During that time, a third of them developed type 2 diabetes. Elevated intact proinsulin at baseline independently predicted who would develop the disease, with about 57% higher odds per standard-deviation increase, even after adjusting for body weight, fasting glucose, and early insulin response.
The Insulin Resistance Atherosclerosis Study (IRAS) followed 903 adults without diabetes for five years. Each standard-deviation increase in intact proinsulin was associated with roughly 90% higher odds of developing diabetes. Those odds held up after adjusting for body mass, glucose tolerance, and insulin sensitivity. People with both high proinsulin and a sluggish early insulin response had the steepest risk.
A population study of 9,396 Finnish men confirmed that both fasting and post-glucose proinsulin levels predicted worsening blood sugar control and new diabetes diagnoses over six years. Proinsulin captures something distinct from simple insulin resistance: it reflects a processing defect inside the beta cell itself.
Proinsulin does not just predict diabetes. It independently predicts cardiovascular events and death, even in people whose blood sugar looks fine. A meta-analysis reviewing 19 Western prospective studies of insulin-related markers (three of which specifically measured proinsulin) found that people in the top third of proinsulin levels were about 2.2 times as likely to develop coronary heart disease compared to those in the bottom third.
Sources: Zethelius et al., Circulation 2002; Alssema et al., Diabetes Care 2005; Yudkin et al., Diabetologia 2002.
What makes these findings striking is that standard insulin measurements did not show the same predictive power. In the Uppsala study, specific insulin was not a significant predictor of coronary death. Proinsulin captured a risk dimension that insulin alone missed.
The cardiovascular signal extends to stroke. In a study of 1,151 elderly men followed for nearly nine years, each standard-deviation increase in fasting proinsulin was linked to about 22% higher risk of stroke or transient ischemic attack (a brief episode where blood flow to the brain is temporarily blocked), even after adjustment for diabetes, high blood pressure, and other established risk factors. A separate case-control study in northern Sweden found that high proinsulin preceded first-ever stroke with roughly 3.4 times the odds compared to low levels. Women in that study showed an especially large signal.
A disproportionately high proinsulin-to-insulin ratio is a hallmark of the cluster of metabolic problems that often travel together: high blood pressure, elevated triglycerides, low HDL cholesterol, and impaired glucose tolerance. The ratio increases as more of these features accumulate. A fasting intact proinsulin above 10 pmol/L (a unit for very small concentrations in blood) was very accurate at ruling in insulin resistance when present (93 to 100% specificity) in people with type 2 diabetes, though it only caught about half of cases (47 to 49% sensitivity).
A common misconception is that elevated proinsulin simply reflects the increased secretory demand of obesity. Research contradicts this. Obese individuals without diabetes actually had lower proinsulin-to-insulin ratios than lean individuals, showing that their beta cells were keeping up with the extra demand. Disproportionate hyperproinsulinemia signals a processing defect inside the beta cell, not just overwork.
If you have a parent or sibling with type 2 diabetes, your beta cells may already be showing subtle strain even if your glucose is perfectly normal. A study of nondiabetic offspring of diabetic parents found that proinsulin levels and the proinsulin-to-insulin ratio were disproportionately elevated compared to controls, pointing to early processing problems that standard glucose testing would not detect. Separate research showed that this elevation can appear at glucose levels still well within the normal range, around 96 to 98 mg/dL.
Proinsulin assays are not standardized across laboratories, so the exact numbers on your report will depend on which test your lab uses. Always compare results within the same lab over time rather than against a universal threshold. That said, published research provides useful orientation.
These tiers are drawn from published research. Your lab may use different assays and cutpoints. Compare your results within the same lab over time for the most meaningful trend. A validated ELISA assay in healthy, non-obese adults established a fasting reference range of 2.7 to 14.2 pmol/L during a standard glucose tolerance test.
Proinsulin has high biological variability. Data from the Hoorn Study showed that the test-to-test variation for fasting proinsulin is approximately 100% of the median value, meaning that in someone with a typical level of 8 pmol/L, a second fasting draw could plausibly come back anywhere from near zero to 16 pmol/L. This variation comes primarily from genuine biological fluctuations rather than lab error. Modern assays have analytical precision well under 10%, so the measurement itself is reliable; it is your body's output that varies from day to day.
This makes serial tracking essential. A single reading can be misleading in either direction. Get a fasting baseline, then retest in three to six months if you are making dietary or exercise changes. After that, annual monitoring gives you a trajectory that is far more informative than any individual number. If you see a rising trend over two or three draws, that pattern tells you more than a single elevated result.
Several factors can distort a single proinsulin reading and lead you to the wrong conclusion.
Your background can affect what your proinsulin number means. A study comparing African American and European American adults found that African Americans had higher fasting and post-glucose proinsulin-to-C-peptide ratios even after adjusting for insulin sensitivity. The relationship between proinsulin processing and beta cell function also differed by ethnicity: the proinsulin-to-C-peptide ratio predicted beta cell efficiency only in African Americans, not in European Americans. These differences mean that a single set of cutpoints may not apply equally across populations.
Evidence-backed interventions that affect your Proinsulin level
Proinsulin is best interpreted alongside these tests.